H
Henry H. Gu
Researcher at Bristol-Myers Squibb
Publications - 33
Citations - 808
Henry H. Gu is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: IMP dehydrogenase & Acridone. The author has an hindex of 19, co-authored 33 publications receiving 794 citations.
Papers
More filters
Patent
Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
Chunjian Liu,T. G. Murali Dhar,Henry H. Gu,Edwin J. Iwanowicz,Katerina Leftheris,William J. Pitts +5 more
TL;DR: In this paper, the identification of novel inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase) was presented. But the authors did not identify the drugs that were useful in treating or preventing the disease, such as transplant rejection and autoimmune diseases.
Patent
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
TL;DR: In this article, the authors present novel heterocyclo-substituted imidazopyrazines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
Journal ArticleDOI
Imidazoquinoxaline Src-Family Kinase p56Lck Inhibitors: SAR, QSAR, and the Discovery of (S)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity
Ping Chen,Arthur M. Doweyko,Derek J. Norris,Henry H. Gu,Steven H. Spergel,Jagabundhu Das,Robert V. Moquin,James Lin,John Wityak,Edwin J. Iwanowicz,Kim W. McIntyre,David J. Shuster,Kamelia Behnia,Saeho Chong,Henry F. De Fex,Suhong Pang,Sydney Pitt,Ding Ren Shen,Sara Thrall,Paul L. Stanley,O. Kocy,Mark R. Witmer,Steven B. Kanner,Gary L. Schieven,Joel C. Barrish +24 more
TL;DR: A series of novel anilino 5-azaimidazoquinoxaline analogues possessing potent in vitro activity against p56Lck and T cell proliferation have been discovered and the H-bonding contribution to observed binding affinities within a tightly congeneric series was found to be significant.
Journal ArticleDOI
Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419).
Scott H. Watterson,Ping Chen,Yufen Zhao,Henry H. Gu,T. G. Murali Dhar,Zili Xiao,Shelley K. Ballentine,Zhongqi Shen,Catherine A. Fleener,Katherine A. Rouleau,Mary T. Obermeier,Zheng Yang,Kim W. McIntyre,David J. Shuster,Mark R. Witmer,Donna M. Dambach,Sam T. Chao,Arvind Mathur,Bang-Chi Chen,Joel C. Barrish,Jeffrey A. Robl,and Robert Townsend,Edwin J. Iwanowicz +22 more
TL;DR: This article will detail the discovery and SAR leading to a novel and potent acridone-based IMPDH inhibitor 4m and its efficacy and GI tolerability when administered orally in a rat adjuvant arthritis model.
Journal ArticleDOI
Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase.
William J. Pitts,Junqing Guo,T. G. Murali Dhar,Zhongqi Shen,Henry H. Gu,Scott H. Watterson,Mark S. Bednarz,Bang Chi Chen,Joel C. Barrish,Donna A. Bassolino,Daniel L. Cheney,Catherine A. Fleener,Katherine A. Rouleau,Diane Hollenbaugh,Edwin J. Iwanowicz +14 more
TL;DR: A series of novel triazine-based small molecule inhibitors (IV) of inosine monophosphate dehydrogenase was prepared and the structure-activity relationships derived from in vitro studies are described.